Regencell Bioscience (NASDAQ:RGC) Trading Up 11.1% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price was up 11.1% on Thursday . The stock traded as high as $30.96 and last traded at $30.6610. Approximately 189,889 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 332,522 shares. The stock had previously closed at $27.59.

Key Headlines Impacting Regencell Bioscience

Here are the key news stories impacting Regencell Bioscience this week:

• Positive Sentiment: Regencell reported quarterly EPS of $0.00, which removes near-term earnings disappointment, though it does not provide a strong growth catalyst. MarketBeat earnings report
• Neutral Sentiment: Multiple law firms reiterated deadlines for investors in an existing class action tied to Regencell securities purchased between October 28, 2024 and October 31, 2025. These notices mainly update shareholders on legal options rather than company operations. Pomerantz class action filing
• Neutral Sentiment: Other firms, including Rosen, Schall, Faruqi & Faruqi, and Glancy Prongay Wolke & Rotter, continued reminding investors of the June 23, 2026 lead-plaintiff deadline, adding to legal overhang but not introducing new operational news. Schall Law Firm notice
• Negative Sentiment: The biggest drag on RGC appears to be the ongoing securities-fraud litigation and related investor-loss marketing, which can weigh on sentiment and increase uncertainty around the stock. Robbins LLP notice

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Regencell Bioscience currently has an average rating of “Sell”.

Regencell Bioscience Stock Down 7.0%

The company has a fifty day moving average price of $27.18 and a two-hundred day moving average price of $23.85.

Regencell Bioscience (NASDAQ:RGC) last announced its quarterly earnings data on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

A number of large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new stake in Regencell Bioscience in the second quarter valued at $1,701,000. BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience in the second quarter valued at $768,000. XTX Topco Ltd acquired a new stake in Regencell Bioscience in the third quarter valued at $598,000. Vident Advisory LLC lifted its stake in Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience in the fourth quarter valued at $275,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.